deltatrials
Recruiting PHASE4 INTERVENTIONAL 1-arm NCT05648591

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Open-label Safety Study of a 1-year 8 to 24 mg/Day Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder

Sponsor: Vanda Pharmaceuticals

Conditions Bipolar I Disorder Schizophrenia
Interventions Iloperidone
Updated 6 times since 2023 Last updated: Feb 27, 2025 Started: May 24, 2023 Primary completion: Mar 31, 2026 Completion: Nov 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05648591, this PHASE4 trial focuses on Bipolar I Disorder and Schizophrenia and remains actively recruiting participants. Sponsored by Vanda Pharmaceuticals, it has been updated 6 times since 2023, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshotRecruiting~Jul 2023 – ~Apr 2024 · 9 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotRecruiting~Apr 2025 – present · 13 months · monthly snapshotRecruiting

Change History

6 versions recorded

  1. Apr 2025 — Present [monthly]

    Recruiting PHASE4

  2. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  4. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE4

  5. Jul 2023 — Apr 2024 [monthly]

    Recruiting PHASE4

▶ Show 1 earlier version

  1. Jan 2023 — Jul 2023 [monthly]

    Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vanda Pharmaceuticals
Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations